Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer

Breast Cancer Research and Treatment

Volumn 128, Issue 3, 2011, Pages 713-723

  Pérez Tenorio, Gizeh ^a   Karlsson, Elin ^a   Waltersson, Marie Ahnström ^a   Olsson, Birgit ^a   Holmlund, Birgitta ^a   Nordenskjöld, Bo ^a   Fornander, Tommy ^b   Skoog, Lambert ^b   Stål, Olle ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

11q13; 17q21 23; Gene amplification; mTOR; S6 kinase; Tamoxifen response

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; METHOTREXATE; PROGESTERONE RECEPTOR; PROTEIN S6K1; PROTEIN S6K2; S6 KINASE; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER CELL; CANCER STAGING; CCND1 GENE; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; FEMALE; GENE; GENE AMPLIFICATION; GENE DUPLICATION; GENE EXPRESSION; GENE NUMBER; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REGULATOR GENE; S6K1 GENE; S6K2 GENE; TREATMENT RESPONSE;

BREAST NEOPLASMS; DNA COPY NUMBER VARIATIONS; FEMALE; GENE AMPLIFICATION; HUMANS; PROGNOSIS; RECURRENCE; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SURVIVAL ANALYSIS; TOR SERINE-THREONINE KINASES;

EID: 79960838434     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1058-x     Document Type: Article

References (52)

1. XM Ma J Blenis 2009 Molecular mechanisms of mTOR-mediated translational control Nat Rev Mol Cell Biol 10 307 318 19339977 10.1038/nrm2672
2. DA Guertin DM Sabatini 2007 Defining the role of mTOR in cancer Cancer Cell 12 9 22 17613433 10.1016/j.ccr.2007.05.008 1:CAS:528:DC%2BD2sXotVyqsr0%3D (Pubitemid 47001784)
3. G Perez-Tenorio L Alkhori B Olsson MA Waltersson B Nordenskjöld LE Rutqvist L Skoog O Stål 2007 PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer Clin Cancer Res 13 3577 3584 17575221 10.1158/1078-0432.CCR-06-1609 1:CAS:528:DC%2BD2sXmsFCqtbk%3D (Pubitemid 46955118)
4. LH Saal K Holm M Maurer L Memeo T Su X Wang JS Yu PO Malmström M Mansukhani J Enoksson H Hibshoosh Å Borg R Parsons 2005 PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma Cancer Res 65 2554 2559 15805248 10.1158/0008-5472-CAN-04-3913 1:CAS:528:DC%2BD2MXjtVeqsrc%3D (Pubitemid 40490050)
5. Y Samuels Z Wang A Bardelli N Silliman J Ptak S Szabo H Yan A Gazdar SM Powell GJ Riggins JK Willson S Markowitz KW Kinzler B Vogelstein VE Velculescu 2004 High frequency of mutations of the PIK3CA gene in human cancers Science 304 554 15016963 10.1126/science.1096502 1:CAS:528:DC%2BD2cXjsVGmsbk%3D (Pubitemid 38541907)
6. M Bärlund A Boulay J Rudloff J Ye S Zumstein-Mecker T O'Reilly DB Evans S Chen HA Lane 2005 Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer Clin Cancer Res 11 5319 5328 10.1158/1078-0432.CCR-04-2402 (Pubitemid 41003721)
7. H Kurokawa CL Arteaga 2003 ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms Clin Cancer Res 9 511S 515S 12538508 1:CAS:528:DC%2BD3sXnt1yisw%3D%3D (Pubitemid 36105795)
8. R Schiff SA Massarweh J Shou L Bharwani SK Mohsin CK Osborne 2004 Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance Clin Cancer Res 10 331S 336S 14734488 10.1158/1078-0432.CCR-031212 1:CAS:528:DC%2BD2cXkvF2ksw%3D%3D (Pubitemid 38116639)
9. S Chan ME Scheulen S Johnston K Mross F Cardoso C Dittrich W Eiermann D Hess R Morant V Semiglazov M Borner M Salzberg V Ostapenko HJ Illiger D Behringer N Bardy-Bouxin J Boni S Kong M Cincotta L Moore 2005 Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer J Clin Oncol 23 5314 5322 15955899 10.1200/JCO.2005.66.130 1:CAS:528:DC%2BD2MXpslOrtLo%3D (Pubitemid 46206985)
10. LA deGraffenried WE Friedrichs DH Russell EJ Donzis AK Middleton JM Silva RA Roth M Hidalgo 2004 Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity Clin Cancer Res 10 8059 8067 15585641 10.1158/1078-0432.CCR-04-0035 1:CAS:528:DC%2BD2cXhtVCrs7vN (Pubitemid 39587547)
11. J Baselga V Semiglazov P van Dam A Manikhas M Bellet J Mayordomo M Campone E Kubista R Greil G Bianchi J Steinseifer B Molloy E Tokaji H Gardner P Phillips M Stumm HA Lane JM Dixon W Jonat HS Rugo 2009 Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer J Clin Oncol 27 2630 2637 19380449 10.1200/JCO.2008.18.8391 1:CAS:528:DC%2BD1MXnslWit7s%3D
12. IH Park R Bachmann H Shirazi J Chen 2002 Regulation of ribosomal S6 kinase 2 by mammalian target of rapamycin J Biol Chem 277 31423 31429 12087098 10.1074/jbc.M204080200 1:CAS:528:DC%2BD38XmslOqsLo%3D (Pubitemid 34968942)
13. K Jastrzebski KM Hannan EB Tchoubrieva RD Hannan RB Pearson 2007 Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function Growth Factors 25 209 226 18092230 10.1080/08977190701779101 1:CAS:528:DC%2BD2sXhsVCgsbbN
14. KK Lee-Fruman CJ Kuo J Lippincott N Terada J Blenis 1999 Characterization of S6K2, a novel kinase homologous to S6K1 Oncogene 18 5108 5114 10490847 10.1038/sj.onc.1202894 1:CAS:528:DyaK1MXmtlart78%3D (Pubitemid 29443756)
15. H Shima M Pende Y Chen S Fumagalli G Thomas SC Kozma 1998 Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase EMBO J 17 6649 6659 9822608 10.1093/emboj/17.22.6649 1:CAS:528:DyaK1cXnvF2jt70%3D (Pubitemid 28521798)
16. J Montagne MJ Stewart H Stocker E Hafen SC Kozma G Thomas 1999 Drosophila S6 kinase: a regulator of cell size Science 285 2126 2129 10497130 10.1126/science.285.5436.2126 1:CAS:528:DyaK1MXmt12jsLY%3D (Pubitemid 29451430)
17. M Pende SH Um V Mieulet M Sticker VL Goss J Mestan M Mueller S Fumagalli SC Kozma G Thomas 2004 S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway Mol Cell Biol 24 3112 3124 15060135 10.1128/MCB.24.8.3112-3124.2004 1:CAS:528: DC%2BD2cXjtFKjsb8%3D (Pubitemid 38452057)
18. FJ Lofts WJ Gullick 1992 c-erbB2 amplification and overexpression in human tumors Cancer Treat Res 61 161 179 1360230 1:CAS:528:DyaK3sXitFShuro%3D
19. TP Singleton JG Strickler 1992 Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene Pathol Annu 27 Pt 1 165 190 1346551 1:STN:280:DyaK387ktVyqsQ%3D%3D
20. DJ Slamon GM Clark SG Wong WJ Levin A Ullrich WL McGuire 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 182 3798106 10.1126/science.3798106 1:CAS:528:DyaL2sXhtVSht7s%3D (Pubitemid 17231334)
21. K Al-Kuraya P Schraml J Torhorst C Tapia B Zaharieva H Novotny H Spichtin R Maurer M Mirlacher O Kochli M Zuber H Dieterich F Mross K Wilber R Simon G Sauter 2004 Prognostic relevance of gene amplifications and coamplifications in breast cancer Cancer Res 64 8534 8540 15574759 10.1158/0008-5472.CAN-04-1945 1:CAS:528:DC%2BD2cXhtVCjs7zJ (Pubitemid 39552065)
22. J Bostner M Ahnström Waltersson T Fornander L Skoog B Nordenskjöld O Stål 2007 Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer Oncogene 26 6997 7005 17486065 10.1038/sj.onc.1210506 1:CAS:528:DC%2BD2sXht1Wgt7rJ (Pubitemid 350014611)
23. K Jirström M Stendahl L Ryden A Kronblad PO Bendahl O Stål G Landberg 2005 Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification Cancer Res 65 8009 8016 16140974 (Pubitemid 41297281)
24. M Bärlund F Forozan J Kononen L Bubendorf Y Chen ML Bittner J Torhorst P Haas C Bucher G Sauter OP Kallioniemi A Kallioniemi 2000 Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis J Natl Cancer Inst 92 1252 1259 10922410 10.1093/jnci/92.15.1252 (Pubitemid 30627733)
25. JA van der Hage LJ van den Broek C Legrand PC Clahsen CJ Bosch EC Robanus-Maandag CJ van de Velde MJ van de Vijver 2004 Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients Br J Cancer 90 1543 1550 15083183 10.1038/sj.bjc.6601741 (Pubitemid 38648236)
26. WC Noh YH Kim MS Kim JS Koh HA Kim NM Moon NS Paik 2008 Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables Breast Cancer Res Treat 110 477 483 17805960 10.1007/s10549-007-9746-x 1:CAS:528:DC%2BD1cXosVOgtL4%3D (Pubitemid 351962593)
27. LM McShane DG Altman W Sauerbrei SE Taube M Gion GM Clark 2006 REporting recommendations for tumor MARKer prognostic studies (REMARK) Breast Cancer Res Treat 100 229 235 16932852 10.1007/s10549-006-9242-8 (Pubitemid 44631925)
28. LE Rutqvist H Johansson 2006 Long-term follow-up of the Stockholm randomized trials of postoperative radiation therapy versus adjuvant chemotherapy among 'high risk' pre- and postmenopausal breast cancer patients Acta Oncol 45 517 527 16864164 10.1080/02841860600702068 1:CAS:528: DC%2BD28XhtVWrtb%2FO (Pubitemid 44172627)
29. LE Rutqvist H Johansson 2007 Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer Acta Oncol 46 133 145 17453361 10.1080/02841860601034834 1:CAS:528:DC%2BD2sXjs1GlsL0%3D (Pubitemid 46277056)
30. MS Askmalm J Carstensen B Nordenskjöld B Olsson LE Rutqvist L Skoog O Stål 2004 Mutation and accumulation of p53 related to results of adjuvant therapy of postmenopausal breast cancer patients Acta Oncol 43 235 244 15244246 10.1080/02841860410029474 1:CAS:528:DC%2BD2cXlslSlur8%3D (Pubitemid 38757044)
31. A Jansson L Delander C Gunnarsson T Fornander L Skoog B Nordenskjöld O Stål 2009 Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients Clin Cancer Res 15 3610 3616 19401349 10.1158/1078-0432.CCR-08-2599 1:CAS:528:DC%2BD1MXmtVKls7k%3D
32. CS Sinclair M Rowley A Naderi FJ Couch 2003 The 17q23 amplicon and breast cancer Breast Cancer Res Treat 78 313 322 12755490 10.1023/A:1023081624133 1:CAS:528:DC%2BD3sXisFKgsbk%3D (Pubitemid 36543211)
33. FJ Couch XY Wang GJ Wu J Qian RB Jenkins CD James 1999 Localization of PS6K to chromosomal region 17q23 and determination of its amplification in breast cancer Cancer Res 59 1408 1411 10197603 1:CAS:528:DyaK1MXisVWkt7c%3D (Pubitemid 29160100)
34. DG Albertson 2006 Gene amplification in cancer Trends Genet 22 447 455 16787682 10.1016/j.tig.2006.06.007 1:CAS:528:DC%2BD28XntlCksbs%3D (Pubitemid 44093770)
35. S Elsheikh AR Green MA Aleskandarany M Grainge CE Paish MB Lambros JS Reis-Filho IO Ellis 2008 CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome Breast Cancer Res Treat 109 325 335 17653856 10.1007/s10549-007-9659-8 1:CAS:528:DC%2BD1cXlsV2ntr8%3D (Pubitemid 351644857)
36. A Letessier F Sircoulomb C Ginestier N Cervera F Monville V Gelsi-Boyer B Esterni J Geneix P Finetti C Zemmour P Viens E Charafe-Jauffret J Jacquemier D Birnbaum M Chaffanet 2006 Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers BMC Cancer 6 245 17040570 10.1186/1471-2407-6-245 (Pubitemid 44696826)
37. V Lyzogubov Y Khozhaenko V Usenko S Antonjuk G Ovcharenko I Tikhonkova V Filonenko 2005 Immunohistochemical analysis of Ki-67, PCNA and S6K1/2 expression in human breast cancer Exp Oncol 27 141 144 15995633 1:CAS:528: DC%2BD2MXpsVajs7g%3D (Pubitemid 41025737)
38. S Phin D Kupferwasser J Lam KK Lee-Fruman 2003 Mutational analysis of ribosomal S6 kinase 2 shows differential regulation of its kinase activity from that of ribosomal S6 kinase 1 Biochem J 373 583 591 12713446 10.1042/BJ20021794 1:CAS:528:DC%2BD3sXmsFGrtbw%3D (Pubitemid 36897860)
39. S Massarweh R Schiff 2007 Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities Clin Cancer Res 13 1950 1954 17404074 10.1158/1078-0432.CCR-06-2540 1:CAS:528:DC%2BD2sXjs12rsbo%3D (Pubitemid 46649859)
40. RL Yamnik A Digilova DC Davis ZN Brodt CJ Murphy MK Holz 2009 S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation J Biol Chem 284 6361 6369 19112174 10.1074/jbc.M807532200 1:CAS:528:DC%2BD1MXisVSku7s%3D
41. J Jiang N Sarwar D Peston E Kulinskaya S Shousha RC Coombes S Ali 2007 Phosphorylation of estrogen receptor-alpha at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients Clin Cancer Res 13 5769 5776 17908967 10.1158/1078-0432.CCR-07-0822 1:CAS:528:DC%2BD2sXhtFSntL3F (Pubitemid 47583902)
42. H Yamashita M Nishio S Kobayashi Y Ando H Sugiura Z Zhang M Hamaguchi K Mita Y Fujii H Iwase 2005 Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer Breast Cancer Res 7 R753 R764 16168121 10.1186/bcr1285 1:CAS:528:DC%2BD2MXpvFOgtb8%3D
43. D Zhou JJ Ye Y Li K Lui S Chen 2006 The molecular basis of the interaction between the proline-rich SH3-binding motif of PNRC and estrogen receptor alpha Nucleic Acids Res 34 5974 5986 17068076 10.1093/nar/gkl764 1:CAS:528:DC%2BD28Xht1Ohu7bO (Pubitemid 44941176)
44. K Söderlund G Perez-Tenorio O Stål 2005 Activation of the phosphatidylinositol 3-kinase/Akt pathway prevents radiation-induced apoptosis in breast cancer cells Int J Oncol 26 25 32 15586221
45. K Liang Y Lu W Jin KK Ang L Milas Z Fan 2003 Sensitization of breast cancer cells to radiation by trastuzumab Mol Cancer Ther 2 1113 1120 14617784 1:CAS:528:DC%2BD3sXovFCqtLo%3D
46. K Söderlund L Skoog T Fornander MS Askmalm 2007 The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer Radiother Oncol 84 242 251 17707537 10.1016/j.radonc.2007.06.012 (Pubitemid 47371156)
47. JS Russell K Brady WE Burgan MA Cerra KA Oswald K Camphausen PJ Tofilon 2003 Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity Cancer Res 63 7377 7383 14612536 1:CAS:528: DC%2BD3sXovVGltL0%3D (Pubitemid 37413479)
48. T Taki T Ohnishi A Yamamoto S Hiraga N Arita S Izumoto T Hayakawa T Morita 1996 Antisense inhibition of the RAD51 enhances radiosensitivity Biochem Biophys Res Commun 223 434 438 8670299 10.1006/bbrc.1996.0911 1:CAS:528:DyaK28Xjs1yhurg%3D (Pubitemid 26245585)
49. T Ohnishi T Taki S Hiraga N Arita T Morita 1998 In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene Biochem Biophys Res Commun 245 319 324 9571148 10.1006/bbrc.1998.8440 1:CAS:528:DyaK1cXivVOqs7w%3D (Pubitemid 28418498)
50. O Stål S Sullivan S Wingren L Skoog LE Rutqvist JM Carstensen B Nordenskjöld 1995 c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer Eur J Cancer 31A 2185 2190 8652240 10.1016/0959-8049(95)00344-4 (Pubitemid 26050557)
51. O Stål G Perez-Tenorio L Åkerberg B Olsson B Nordenskjöld L Skoog LE Rutqvist 2003 Akt kinases in breast cancer and the results of adjuvant therapy Breast Cancer Res 5 R37 R44 12631397 10.1186/bcr569
52. C Gunnarsson M Ahnström K Kirschner B Olsson B Nordenskjöld LE Rutqvist L Skoog O Stål 2003 Amplification of HSD17B1 and ERBB2 in primary breast cancer Oncogene 22 34 40 12527905 10.1038/sj.onc.1206078 1:CAS:528:DC%2BD3sXjtlCqug%3D%3D (Pubitemid 36152881)